Tweetovi

Blokirali ste korisnika/cu @DrJoelGelfand

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DrJoelGelfand

  1. Poništi
  2. proslijedio/la je Tweet
    prije 7 sati

    ‼️LIVE on March 26th‼️ Register for this FREE webcast & be part of the expert discussion + Q&A session - moderated by - on the new guidelines! Sign up now >>

    Poništi
  3. 82 new hits. PK/PD model for pts w pso on , shows that trough concentration and PASI trajectory at week 4 predicts 6‐month response with the potential for tailoring the dose to the individual patient.

    Poništi
  4. 31. sij
    Poništi
  5. proslijedio/la je Tweet
    30. sij

    50 Years of : Looking back to successfully move forward

    Poništi
  6. 30. sij

    6. HLA-C*06:02 negative psoriasis patients with PsA are 6X more likely to respond to compared to 7. IL36RN, AP1S3 and CARD14 mutations are associated with pustular psoriasis.

    Prikaži ovu nit
    Poništi
  7. 30. sij

    3. 75% of psoriasis heritability is NOT explained by identified loci - much more to discover 4. HLA-B*27 increases risk of PsA in psoriasis, HLA-C*06:02 is not associated with PsA 5. Mendelian randomization studies demonstrate is a causal risk factor for psoriasis

    Prikaži ovu nit
    Poništi
  8. 30. sij

    1. 65 susceptibility loci have been identified. HLA-C*06:02 is most common. 2. IL23R, IL23A, IL12B and TYK2 are pso loci for which drugs targeting these pathways are proven effective for psoriasis

    Prikaži ovu nit
    Poništi
  9. 30. sij

    Want to learn more about ? Check out this review by leaders in the field. Some key points in this tweetorial:

    Prikaži ovu nit
    Poništi
  10. 29. sij
    Poništi
  11. 29. sij

    I am teaching a grad course in patient centered outcomes and effectiveness research this semester. Class is full w 6 from MSCE 1 from K12 & 1 PhD in Demography & Sociology. Interests: onc, peds GI, disparities, global health syllabus attached - going to be a great semester!

    Poništi
  12. 29. sij

    lowers aortic vascular inflammation, and lower IL-6, a key inflammatory maker of CV risk, improves cholesterol profile. None of these treatments influence metabolism

    Prikaži ovu nit
    Poništi
  13. 29. sij

    New recommend earlier use of in psoriasis. RCTs prove and lower in people with

    Prikaži ovu nit
    Poništi
  14. 29. sij

    The is REAL! PsO>PsA>RA when it comes to serious liver outcomes, especially with

    Prikaži ovu nit
    Poništi
  15. 29. sij

    may be mediated by IL-17, is increased in psoriasis, and treatment of periodontitis may improve psoriasis

    Prikaži ovu nit
    Poništi
  16. 29. sij

    What a great time at . I covered the latest advances in including , the , and (see tweetorial for deets). Best part was with the whales!

    Prikaži ovu nit
    Poništi
  17. 20. sij

    63 new hits this week. This paper found that increased predicts events in and normalizes with oral or treatment.

    Poništi
  18. proslijedio/la je Tweet
    17. sij

    TY US Rep 4 candidly sharing your with . Many in the community share similar , & impacts. is critical. patient navigation center is here for anyone needing 2 talk.

    Poništi
  19. 14. sij
    Poništi
  20. 13. sij

    65 new hits. Highlighting this meta-analysis of systemic pso tx. The and were the best for achieving PASI90 at 8-24 wks

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·